ArticleCureus2021
Mycoplasma pneumoniae and Bronchiolitis Obliterans: How a Common Organism Leads to a Rare Pulmonary Disease in Pediatrics.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Clinical and prognostic relevance ofJournal of feline medicine and surgery · 2024Article
- miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection.Archives of microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A rare lung disease, bronchiolitis obliterans (BO) is characterized by airway obstruction and fibrosis of the terminal and respiratory bronchioles. It usually occurs after lung and bone marrow transplants, hematopoietic stem cell transplantation (HSCT), inhalation of toxins, respiratory infections, or in association with several different connective tissue or irritable bowel diseases. When BO is caused by an infection it is referred to as post-infectious bronchiolitis obliterans (PIBO). The prevalence of BO is unknown but has been seen to occur worldwide. The pathophysiology of BO is not fully understood but there is evidence of fibroproliferation leading to abnormal airway remodeling with inflammatory mediators and granulation tissue that narrows the bronchial lumen. Diagnosis of BO is achieved via a combination of clinical manifestations, patient history, pulmonary function test (PFT), radiological imaging, and lung biopsy as the gold standard. Since there is limited literature on pediatric cases with BO and diagnosis may sometimes be challenging, we aim to bring awareness to a pediatric case where PIBO developed after a common pulmonary infection of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.